OTX-2002

mRNA non-vaccine therapeutics field set to reach $2 billion by 2028
Clinical Trials Arena
Tue, 11/8/22 - 10:54 am
MRNA
drug development
Moderna Therapeutics
Ultragenyx
Omega Therapeutics
BioNTech
cancer
OTX-2002
Omega Gets FDA Nod to Start First-Ever Epigenomic Controller Trial
BioSpace
Fri, 07/15/22 - 10:59 am
Omega Therapeutics
hepatocellular carcinoma
OTX-2002
epigenomic controllers
clinical trials